2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03377309 (ClinicalTrials.gov) | December 1, 2019 | 14/12/2017 | Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients | Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients | Amyotrophic Lateral Sclerosis | Drug: Fycompa | American University of Beirut Medical Center | NULL | Terminated | 18 Years | 80 Years | All | 6 | Phase 2 | Lebanon |
| 2 | NCT03020797 (ClinicalTrials.gov) | January 12, 2017 | 15/12/2016 | A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Perampanel;Drug: Placebo Oral Tablet | Stony Brook University | Eisai Inc. | Recruiting | 18 Years | 80 Years | All | 60 | N/A | United States |